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ABSTRACT
Background: Evidence regarding the effects of the omega-3 (ɷ-3)
PUFAs (n–3 PUFAs) DHA and EPA on cognition is lacking.
Objectives: We investigated whether supplementation with oils
rich in EPA or DHA improves cognition, prefrontal cortex (PFC)
hemoglobin (Hb) oxygenation, and memory consolidation.
Methods: Healthy adults (n = 310; age range: 25–49 y) completed
a 26-wk randomized controlled trial in which they consumed
either 900 mg DHA/d and 270 mg EPA/d (DHA-rich oil), 360
mg DHA/d and 900 mg EPA/d (EPA-rich oil), or 3000 mg/d
refined olive oil (placebo). Cognitive performance and memory
consolidation were assessed via computerized cognitive test battery.
PFC Hb oxygenation was measured using near infrared spectroscopy
(NIRS).
Results: Both global accuracy and speed improved with EPA-
rich oil compared with placebo and DHA-rich oil [EPA vs.
placebo accuracy: estimated marginal mean (EMM) = 0.17 (95%
CI: 0.09, 0.24) vs. EMM = 0.03 (95% CI = −0.04, 0.11);
P = 0.044; EPA vs. placebo speed: EMM = −0.15 (95% CI: −0.22,
−0.07) vs. EMM = 0.03 (95% CI: −0.05, 0.10); P = 0.003].
Accuracy of memory was improved with EPA compared with
DHA [EMM = 0.66 (95% CI: 0.26, 1.06) vs. EMM = −0.08
(95% CI: −0.49, 0.33); P = 0.034]. Both EPA- and DHA-rich
oils showed trends towards reduced PFC oxygenated Hb (oxy-Hb)
compared with placebo [placebo: EMM = 27.36 μM (95% CI:
25.73, 28.98); DHA: EMM = 24.62 μM (95% CI: 22.75, 26.48);
P = 0.060; EPA: EMM = 24.97 μM (95% CI: 23.35, 26.59); P =
0.082].
Conclusions: EPA supplementation improved global cognitive
function and was superior to the oil enriched with DHA. Interpreted
within a neural efficiency framework, reduced PFC oxygenated
Hb suggests that n–3 PUFAs may be associated with increased
efficiency. These trials were registered in the clinical trials reg-
istry (https://clinicaltrials.gov/) as NCT03158545, NCT03592251,
NCT02763514. Am J Clin Nutr 2021;00:1–11.
Keywords: eicosapentaenoic acid, docosahexaenoic acid, n-3
polyunsaturated fatty acids, self-micro-emulsifying, cognition,
memory-
Introduction
Evidence from cross-sectional studies suggests that increased
consumption of the bioactive omega-3 (n–3) PUFAs DHA
(22:6n–3) and EPA (20:5n–3) is associated with better cog-
nitive functioning across the life span (1, 2). In the United
Kingdom, like many Western countries, consumption of these
marine-derived long-chain n–3 PUFAs is low (3). Systematic
reviews of clinical trials investigating the effects of n–3
PUFA supplementation on cognition in healthy individuals have
been largely inconclusive, with methodological variations often
cited as underpinning the inconsistency in the evidence (4–6).
Methodological recommendations regarding dose, duration of
intervention, outcome measures, and populations from which
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study samples should be drawn have been proposed elsewhere (4,
5, 7, 8). Emerging evidence also highlights the importance of the
formulation of the interventions themselves for optimal digestion
and absorption to ensure maximal delivery of DHA and EPA to
tissues (9, 10).
To date, most investigations of the cognitive effects of n–
3 PUFAs have focused on DHA, due to its relative abundance
in central nervous system tissue and important structural and
signaling functions therein. However, recent evidence from
short-term trials indicates that treatment with EPA may be
relevant to cognitive function in healthy adults (11, 12). Possibly
underpinning these effects, emerging evidence suggests that EPA
may improve neural efficiency (13) and increase prefrontal cortex
(PFC) hemoglobin (Hb) oxygenation during the performance of
cognitive tasks (14). Moreover, a pilot study that assessed the ef-
fects of 20 wk of supplementation with 1600 mg DHA + 400 mg
EPA daily found that the observed improvement in neurovascular
coupling to a cognitive test battery following the intervention was
correlated with increases in erythrocyte concentrations of EPA,
but not DHA (15). Interestingly, with regard to modulation of
PFC Hb oxygenation during cognitive tasks, results from a pilot
study using continuous wave near infrared spectroscopy (NIRS)
showed an effect of fish oil enriched with DHA but not EPA,
and a dose-dependent increase in PFC Hb oxygenation following
DHA-rich oil in a larger follow-up investigation using the same
technique (16, 17). Direct comparisons of the effects of DHA-
and EPA-enriched interventions in the literature are limited (12,
18), yet this approach would serve to address the aforementioned
disparate findings, and further clarify the specific effects of each
of these fatty acids on cognition.
Therefore, the primary aim of the current trial was to
build upon previous findings (19) by comparing the effects
of treatments enriched with either EPA or DHA, designed for
enhanced absorption, on cognition in healthy young adults who
habitually consume low amounts of oily fish. As a secondary
aim, PFC Hb oxygenation was measured using frequency domain
NIRS. This technique allows for the quantification of changes in
Hb parameters and therefore accurate comparisons of pre- and
postintervention assessments, a limitation of previous research
(16, 17). Finally, an additional exploratory assessment of learning
investigated overnight memory consolidation with the aim of
building on the small number of n–3 PUFA trials that have used
learning-memory tasks to date (20–23).
Methods
This article describes results from 3 trials. Each trial answered
individual research questions and the data from each trial were
analyzed separately. All participants were enrolled into the
cognitive function trial (NCT02763514) and subsamples from
this total sample completed either the NIRS (NCT03158545)
or learning-memory (NCT03592251) assessment components.
The remaining participants took part in assessments of sleep
(NCT03559361) [data published elsewhere (24)].
All 3 trials reported here (NCT03158545, NCT03592251,
and NCT02763514) were conducted at Northumbria University
between October 2016 and November 2018 and adhered to
the guidelines of the Declaration of Helsinki (2013). Ethical
approval for the cognitive function trial (NCT02763514) was
granted by the National Health Service Research Ethics Com-
mittee (Yorkshire and The Humber—Bradford Leeds Research
Ethics Committee) on 12 September 2016; all 3 trials were
granted approval from the Northumbria University Ethics
Committee (SUB067_Patan_230316, SUB087_Patan_080616,
SUB808). Written informed consent was obtained from all
participants.
Participants
Participant disposition through the trial is displayed in
Figure 1. All participants enrolled onto the trials were aged
between 25 and 49 y and had to pass a physical/lifestyle screening
to demonstrate they were in good health. This age cohort was
selected for the trial on the basis that it has been largely over-
looked by previous studies that have tended to focus on children
or older adults, yet a decline in cognitive performance measures is
already apparent in early adulthood (25). Having good health was
identified as being a nonsmoker; free from prescription, herbal,
illicit, or recreational drugs (females taking the contraceptive pill
were included); free from major illnesses; and having a blood
pressure <159/99 mm Hg and a BMI (kg/m2) between 18.5 and
35. Eligible participants consumed oily fish less than once per
week, measured via the DHA food-frequency questionnaire (26),
and reported no habitual consumption of dietary supplements,
including omega-3 supplements. Participants were recruited via
posters, advertisements placed on social media websites, or e-
mails sent out to university staff and students, and were either
students or staff attending/working at Northumbria University or
individuals living in the Newcastle-upon-Tyne surrounding area.
Participant baseline demographic data are provided in Table 1.
A total of 366 males and females were recruited, with 337
being eligible for the study after the screening and training
visit, of whom 310 completed all trial requirements. Of the
27 participants who were withdrawn from the trial, 15 partici-
pants were lost to follow-up, 5 withdrew for personal reasons, 2
were withdrawn after randomization due to having a BMI >35,
2 withdrew due to gastrointestinal upset, 2 withdrew due to an
unrelated illness, and 1 withdrew due to becoming pregnant.
Trial design
All trials used randomized, placebo-controlled, double-blind,
parallel-group designs with participants being randomly assigned
to 1 of 3 treatment groups (placebo oil, DHA-rich oil, or EPA-
rich oil) for a period of 26 wk. All treatment capsules were
supplied by BASF AS. Treatment was 3 capsules/d of ∼1 g
each. For the DHA-rich treatment, the amount of DHA was
at least 300 mg and EPA at least 90 mg/capsule, providing a
total of at least 900 mg DHA/d and 270 mg EPA/d (Accelon™
DHA EE capsules, BASF); for the EPA-rich treatment, the
amount of DHA was at least 120 mg and EPA at least 300 mg
per capsule, providing a total of at least 360 mg DHA/d and
900 mg EPA/d (Accelon™ EPA EE capsules, BASF). Each
of the placebo capsules contained 1000 mg refined olive oil.
The active treatments contained oils derived from fish. The
DHA- and EPA-rich treatments also contained a self–micro-
emulsifying delivery system (SMEDS), a proprietary mixture of
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FIGURE 1 CONSORT flow diagram. ∗Data from the sleep subsample are published elsewhere (24). CONSORT, Consolidated Standards of Reporting
Trials; NIRS, near infrared spectroscopy.
upon reaching the stomach and gastrointestinal tract, resulting
in a larger surface area of the contents upon dispersion in the
gastrointestinal tract. These formulations successfully improve
the bioavailability of the n–3 PUFAs (10). Participants were
instructed to consume their capsules with a glass of water at
night, prior to bedtime. A nighttime dosing regime was selected
based on recent evidence for diurnal rhythms of DHA and EPA
in humans, which suggests optimal times of dosing to maximize
bioavailability (27).
A computer-generated randomization schedule was used to
allocate participants to the treatments (www.randomization.co
m). Placebo and treatment capsules were identical in size and
shape. Capsules were provided in opaque containers that were
coded and distributed by researchers at Northumbria University
according to the randomization schedule. To maintain blinding
throughout the trial, a third party within the university created
the randomization schedule and the coded treatments prior to
their delivery to the research team. Participants were sequentially
allocated a randomization number and unblinding took place
when all analyses were completed.
General demographic information and eligibility criteria
were collected and assessed before participants were accepted
onto the trials. Cognitive assessments, blood samples, NIRS
measurements, and measures of mood were obtained at baseline
and after 26 wk of supplementation. For the subsample enrolled
in the memory consolidation trial (NCT03592251), an additional
assessment took place after 13 wk. Participants were instructed
to maintain their normal diets for the duration of the trials.
Treatment compliance was determined via capsule count of
leftover treatments returned by each participant.
The primary endpoints of the cognitive function study were
accuracy of memory (cognitive function) and subjective mental
fatigue (mood), and the primary endpoint of the NIRS study was
PFC Hb oxygenation. Memory consolidation and associations
between NIRS outcomes and n–3 index were exploratory
outcomes, with all other outcomes being secondary endpoints.
Data were collected from September 2016 to May 2018.
Whole-blood sample collection and assays
Blood samples (6 mL) were collected via venipuncture
into EDTA-coated Vacutainer (Becton, Dickinson U.K.). The
samples were stored in an icebox or at 5◦C and were processed
within 4–8 h of collection. Blood was centrifuged at 2000
rpm (913 × g) for 10 min at room temperature. Following
this, the top layer of plasma was removed using a pastette
and discarded. One milliliter of RBCs was then collected from
the bottom of the evacuated tube, transferred into a 15-mL
centrifuge tube, and made up to 15 mL with PBS. The mixture
was then inverted and centrifuged at 1200 rpm (350 × g)
for 10 min, at room temperature, with a low brake. The PBS
was then removed and the washing process was repeated for a
second time. After the second wash, the remaining RBCs were
transferred into labeled 1.5-mL microtubes and immediately
frozen at −80◦C until analysis. RBC fatty acid composition
was then assessed by GC, as described elsewhere (24, 28). The
fatty acids are expressed as a weight percentage of total fatty
acids present. The n–3 index was calculated as % EPA + %
DHA.
Cognitive assessments
All cognitive tasks were delivered using the Computerized
Mental Performance Assessment System (COMPASS; Northum-
bria University, UK; see: www.cognitivetesting.co.uk). This
testing system can deliver a tailored collection of tasks, with
fully randomized parallel versions of each task administered
during each assessment for each participant. The cognitive tasks
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TABLE 1 Baseline characteristics for the 310 subjects who completed all
aspects of the cognitive function study1
Variable and treatment Mean SD χ2 or F
Males/females, n/n
Placebo 35/66 —




DHA-rich 35.15 8.01 1.25
EPA-rich 35.14 7.88
Systolic BP, mm Hg
Placebo 123.91 12.83
DHA-rich 122.90 12.67 1.09
EPA-rich 121.36 11.95
Diastolic BP, mm Hg
Placebo 81.36 9.69






























DHA-rich 1.14 0.83 1.15
EPA-rich 1.33 1.00
1Baseline differences were assessed using separate 1-factor ANOVAs
or chi-square tests; respective F and χ2 values from these analyses are
presented. No F or χ2 values were significant at the P < 0.05 level. BP,
blood pressure.
sensitive to a wide range of nutritional interventions, including n–
3 PUFAs (19). The cognitive tasks that were completed included
word recall, picture recognition, verbal fluency, simple reaction
time, numeric working memory, Stroop, word recognition,
serial subtract 3s and 7s, rapid visual information processing
(RVIP), location learning, digit vigilance, and peg and ball. The
cognitive demand battery was made up of 4 repetitions of the
following tasks: serial subtract 3s, serial subtract 7s and RVIP.
Outcomes from individual tasks were used to derive the following
composite cognitive domain measures: accuracy of attention,
speed of attention, accuracy of memory, speed of memory, global
accuracy, and global speed.
For all cognitive domains, z scores were calculated by pooling
baseline and 26-wk data, as previously described (19, 22). z
Scores were clustered into cognitive domains as follows:
1. Accuracy of attention = (Z-Stroop accuracy + Z-RVIP
average accuracy) ÷ 2
2. Speed of attention = [Z-Stroop reaction time (RT) + Z-
RVIP average RT + Z-simple RT (SRT) ] ÷ 3
3. Accuracy of memory = (Z-immediate word recall ac-
curacy + Z-delayed word recall accuracy + Z-word
recognition accuracy + Z-picture recognition accuracy)
÷ 4
4. Speed of memory = (Z-word recognition RT + Z-picture
recognition RT) ÷ 2
5. Global accuracy = (Z-immediate word recall accuracy + Z-
delayed word recall accuracy + Z-word recognition
accuracy + Z-picture recognition accuracy + Z-verbal
fluency accuracy + Z-Stroop accuracy + Z-numneric
working memory (NWM) accuracy + Z-RVIP average
accuracy) ÷ 8
6. Global speed = (Z-word recognition RT + Z-picture
recognition RT + Z-Stroop RT + Z-SRT + Z-NMW
RT + Z-RVIP average RT) ÷ 6
Individual task outcomes [e.g., accuracy (percentage of correct
responses made), RT (ms), false alarms (number)] were also
assessed. The full battery of tasks took ∼1 h to administer. See
online Supplemental Material under “Supplementary method,
section 1.2” for detailed descriptions of each individual task.
The cognitive testing was conducted under rigorously con-
trolled conditions (see Supplemental Material under “Supple-
mentary method, section 1.4”). In brief, assessments at baseline
and 26 wk were completed at either 07:00, 08:30, or 10:00 h.
Participants were scheduled to complete the week 26 assessment
at the same time as their baseline assessment, although this was
not possible for a small number of participants. Participants were
instructed to avoid caffeinated food and beverages for 18 h,
alcohol for 24 h, and antihistamines for 48 h prior to the baseline
and 26-wk assessments. Environmental factors such as noise and
temperature were controlled to avoid any distraction during tests.
During their screening visit, participants were instructed on the
procedure for the administration of the cognitive battery and
undertook a training session comprising a battery of shortened
tasks where each “mini task” was completed 3 times in succession
to familiarize them with the procedure for each task and 2 full-
length parallel versions of the test battery to mitigate potential
learning effects. Each participant had to meet minimum speed
and accuracy requirements on each task before proceeding to the
intervention phase.
NIRS assessment
The NIRS assessment was conducted in a subsample of 78
participants, which took place within 1.5 h of completing the
cognitive assessment at baseline and 26 wk. NIRS measures
were taken at rest and during completion of serial subtraction
tasks of varying difficulties [3s, 7s, 17s; confirmed via “task
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response was measured using NIRS (OxiplexTS Frequency-
Domain Near-Infrared Tissue Oximeter; ISS Inc.). This system
provides absolute measurements of the absorption of the near-
infrared light emitted at 2 distinct wavelengths by the device,
which allows for the quantification of oxygenated Hb (oxy-Hb)
and deoxygenated Hb (deoxy-Hb) via their differing photon-
absorption properties. These values can then be used to determine
total Hb (t-Hb; oxy-Hb+deoxy-Hb) and oxygen saturation
percentage (Ox%; oxy-Hb/t-Hb × 100). This system can be used
for quantifying changes in hemodynamic response during both
acute (i.e., changes in response to cognitive tasks) and chronic
(i.e., comparing pre- and 26 wk postintervention time points)
assessments.
Light was emitted at 691 and 830 nm by optical fibers glued in
pairs to 4 prisms (8 fibers in total) separated from the collector
bundle, which was also glued to a prism, by 2.0, 2.5, 3.0, or
3.5 cm. Each of the emitter and collector bundle prisms were
embedded into a flexible polyurethane resin to form a sensor, with
overall dimensions of 7.6 cm × 2.5 cm × 0.3 cm. Two identical
sensors were attached to each side of the participants’ foreheads
and secured in place with a self-adhering bandage. The sensors
were positioned so that the bottom edge was level with the top
of the participants’ eyebrows and the middle edge touching at
the midline of the forehead. Data were collected at a rate of 5 Hz
and were measured in micromolars (μM). When used in this way,
increases in oxy-Hb and t-Hb are usually interpreted as increased
activation of the PFC (29).
Memory consolidation assessment
The memory consolidation assessment was an exploratory
arm of the investigation conducted in a subsample of 169
participants at baseline and 13 and 26 wk postintervention. A
similar trial design to that used previously (30, 31) was used
to measure overnight memory consolidation and was adapted
within the current trial to be administered via COMPASS on a
tablet computer. This involved completion of 2 learning tasks
prior to going to sleep and completion of respective recall
tasks the following morning. In addition, attention (simple RT,
digit vigilance) and executive function (peg and ball) tasks
and subjective morning alertness (VAS) were assessed upon
waking, also via the tablet computer. Task details and scoring are
described in full under “Supplementary method, sections 1.2.11,
1.2.12 and in Supplementry Figure 1”.
Statistical analysis
Statistical analyses were performed with IBM SPSS statistics
software (version 25; IBM Corporation). Data handling and
cleaning procedures are described in full in the Supplemental
Material under “Supplementary method, section 1.5.” Descrip-
tive and comparison statistics (independent t test, 2-tailed or
chi-square test) of all baseline characteristics were based on all
participants who provided data that could be analyzed (intention-
to-treat population). The general statistical approach was via
linear mixed models (LMMs). LMMs have several advantages
over using repeated-measures ANOVA or ANCOVA including
the ability to accommodate missing data points often encountered
in longitudinal datasets and the ability to model nonlinear,
individual characteristics (32). Therefore, data were analyzed
using the MIXED procedure in SPSS unless another analysis is
stated. For each model, restricted maximum likelihood estimation
methods were used and covariance matrix structure was chosen
based on the structure that produced the lowest Schwarz’s
Bayesian Criterion (BIC), an indication of the best-fitting model
for the data (33). Changes within outcome variables during the
treatment period were assessed via LMMs that adjusted for
respective baseline preintervention scores. For each of the models
conducted throughout the analysis, age, years in education, and
baseline n–3 index were built into the model as covariates if
they were identified as having a significant impact (P < 0.05)
on the dependent variable, to control for the impact of these
variables within the model. Participant was also entered as
a random effect in each model if it lowered the BIC value,
suggesting an improved model fit. Significant main or interaction
effects of treatment (P < 0.05) were investigated further
with Sidak-corrected comparisons to account for multiple-group
comparisons. Full descriptions of each LMM are outlined
in section 1.6 of the Supplementary method (Supplemental
Material).
Using GPower 3.1.3, a priori sample sizes, based on ANOVA,
were calculated for each study separately, based on the range
of small to medium effect size estimates seen previously (e.g.,
19, 34), at 80% power and an ɑ level of 0.05. In addition, an
extra 10% was added to each estimate to allow for dropouts. The
total sample size for the cognitive study was 336 participants
(f = 0.18), 78 participants for the NIRS study (f = 0.32) and
168 participants for the memory consolidation study (f = 0.13).
In addition, a post hoc power calculation for the mixed-effects
model analysis that was applied to the cognitive data, computed
using the online program RMASS (www.rmass.org/), at 80%
power, an ɑ level of 0.05, a small to medium effect size,
and an attrition rate of 10%, confirmed a total sample size of
300 participants (35).
For the cognitive function, mood, and memory consolidation
assessments, outcome data from each task and VAS were
analyzed. In addition, the cognitive function data were also
analyzed via the 6 cognitive domains described above.
NIRS data (Ox%, t-Hb, oxy-Hb, and deoxy-Hb) were split
into 2 distinct periods: resting and active. The resting period
contained the averaged data from the 5-min resting period before
the cognitive tasks began and the active period consisted of the
averaged data from all 3 repetitions of the serial 3s, serial 7s,
and serial 17s subtraction tasks. The cognitive and subjective task
difficulty data collected during the NIRS assessments consisted
of the average number of correct responses, accuracy %, and task
difficulty % from all 3 repetitions of the serial 3s, 7s, and 17s
tasks.
Efficiency index (EI) was calculated by standardizing the raw
active NIRS data (Ox%, t-Hb, oxy-Hb, and deoxy-Hb) and the
accuracy % for every task during each visit to a value of 0–1
(1 = the highest accuracy % or highest respective NIRS value).
Once these new standardized values had been calculated, each
participant’s standardized NIRS value was then subtracted from
their standardized accuracy % for each task. This then provided
an EI score of between −1 and 1 for each NIRS parameter (Ox%,
t-Hb, oxy-Hb, and deoxy-Hb), with higher scores indicating
greater neural efficiency. These EI calculations have been used
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TABLE 2 RBC fatty acid outcomes by treatment group1
Variable Baseline (n = 285) Week 26 (n = 272) Change2 (n = 263) F value3
% of EPA in RBCs
Placebo 0.88 ± 0.32 0.85 ± 0.36 − 0.03 ± 0.36 152.384
DHA-rich 0.86 ± 0.35 2.07 ± 0.82 1.21 ± 0.72
EPA-rich 0.87 ± 0.42 2.68 ± 1.05 1.87 ± 0.98
% of DHA in RBCs
Placebo 4.98 ± 1.09 4.73 ± 1.03 − 0.19 ± 0.95 111.244
DHA-rich 4.81 ± 1.19 7.43 ± 1.57 2.61 ± 1.56
EPA-rich 5.00 ± 1.26 6.03 ± 1.05 1.04 ± 1.16
n–3 Index (EPA+DHA)
Placebo 5.86 ± 1.28 5.58 ± 1.21 − 0.21 ± 1.12 134.754
DHA-rich 5.68 ± 1.41 9.50 ± 2.25 3.81 ± 2.04
EPA-rich 5.87 ± 1.52 8.71 ± 1.80 2.91 ± 1.84
1Means ± SDs of the raw blood data are presented for DHA, EPA, and n–3 index at baseline, week 26, and
change values.
2Change values are only calculated for those participants who successfully provided data at both baseline and
week 26.
3F values for change data from 1-factor ANOVA are presented.
4P < 0.001.
The models used to analyze the cognitive function trial
data consisted of treatment (DHA-rich, EPA-rich, placebo). The
models used to analyze the NIRS data consisted of treatment
(DHA-rich, EPA-rich, placebo), hemisphere (left, right), task
(3s, 7s, 17s), and task randomization order (1–6). The models
used to analyze the memory consolidation trial data consisted of
treatment (DHA-rich, EPA-rich, placebo) and visit (week 13 or
week 26). Respective baseline values were also entered into every
model as a covariate. Full descriptions of the fixed factors and
covariates appearing in each respective model are reported in full
in the Supplemental Material under “Supplementary methods,
section 1.6.”
The primary focus of all analyses was placebo comparisons
with both the DHA- and EPA-rich treatments. However, the
design of each of the trials also offered the opportunity to
compare the effects of the 2 active treatments. Therefore,
comparisons between placebo and the active treatment groups,
as well as comparisons between the 2 active groups, are
reported.
Exploratory NIRS correlations
Pearson’s bivariate correlations were conducted post hoc
to further explore the relation between n–3 index and NIRS
outcomes. Correlations were therefore conducted between n–3
index and NIRS measures (Ox%, t-Hb, oxy-Hb, and deoxy-Hb)
during each of the subtraction tasks (3s, 7s, or 17s), for each
hemisphere (left or right) and for each of the visits (baseline or
week 26).
Results
Overall, of the 337 participants who were randomly assigned
to treatments, 27 were lost to follow-up or discontinued the
intervention for various reasons (n = 11 in the placebo group,
n = 8 in the DHA-rich group, n = 8 in the EPA-rich group)
(Figure 1). The main cognitive function analysis was conducted
in 310 participants (n = 101 in the placebo group, n = 105 in
the DHA-rich group, n = 104 in the EPA-rich group) for whom
baseline and end data were available. For the NIRS subsample,
the final analysis was conducted in 75 participants (n = 25 in
the placebo group, n = 25 in the DHA-rich group, n = 25 in the
EPA-rich group) for whom baseline and end data were available.
For the memory consolidation subsample, the final analysis was
conducted in 155 participants for whom baseline and data from at
least 1 of the postintervention assessments (week 13 or 26) were
available (n = 51 in the placebo group, n = 51 in the DHA-rich
group, n = 53 in the EPA-rich group). Baseline characteristics of
participants are summarized in Table 1. No significant differences
between the treatment groups were identified for any of the
baseline demographics.
For participants who completed the trial, compliance was high
in all 3 groups (96.06% placebo, 97.43% DHA-rich, 96.57%
EPA-rich) with 1-factor ANOVA identifying no significant dif-
ferences for compliance percentage by treatment group [F(2,306)
= 1.39, P = 0.250]. A chi-square test was also conducted
on the responses to the treatment guess questionnaire that was
completed at the end of the final visit and revealed no significant
differences in participants’ ability to correctly identify whether
they had been administered an active or placebo treatment
between the 3 groups [χ2(2) = 1.52, P = 0.467]. Analysis of
RBC fatty acid profiles further supports the compliance data
(Table 2).
A similar number of adverse events was reported in each group
(placebo, n = 15; DHA, n = 20; EPA, n = 17). Most of these were
mild ailments (e.g., headache, aches and pains, common cold).
Ten participants reported gastrointestinal issues (placebo, n = 3;
DHA, n = 5; EPA, n = 2). One participant was withdrawn due
to pregnancy. Adverse events resulting in participant withdrawal
are shown in Figure 1.
Cognition
A significant effect of treatment for global accuracy was
identified [F(2, 215) = 4.82, P = 0.009], with post hoc
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FIGURE 2 Estimated marginal means ± SEs from LMM analysis for
post-dose (A) global accuracy (average standardized % accuracy scores
across all cognitive tasks), (B) global speed (average standardized reaction
time across all cognitive tasks), and (C) accuracy of memory (average
standardized % accuracy across all the memory tasks). ∗P < 0.05. LMM,
linear mixed model.
EPA-rich group (estimated marginal mean [EMM] = 0.17; 95%
CI = 0.09, 0.24) compared with both the placebo (EMM = 0.03;
95% CI = −0.04, 0.11; P = 0.044) and DHA-rich (EMM = 0.01;
95% CI = −0.07, 0.09; P = 0.013) groups (Figure 2A).
In addition, a significant effect of treatment for global speed
was identified [F(2, 255) = 5.74, P = 0.004], with post hoc
comparisons identifying significantly faster reaction times in the
EPA-rich group (EMM = −0.15; 95% CI = −0.22, −0.07)
compared with the placebo group (EMM = 0.03; 95% CI =
−0.05, 0.10; P = 0.003) and a trend towards significantly faster
reaction times compared with the DHA-rich groups (EMM =
−0.03; 95% CI = −0.10, 0.05; P = 0.062) (Figure 2B).
A significant effect of treatment for accuracy of memory
was identified [F(2, 290) = 3.28, P = 0.039], with post
hoc comparisons showing significantly higher accuracy in the
FIGURE 3 Estimated marginal means ± SEs from LMM analysis for
word recognition RT during the learning trials. ∗P < 0.05. LMM, linear mixed
model; RT, reaction time.
EPA-rich group (EMM = 0.66; 95% CI = 0.26, 1.06) compared
with the DHA-rich group (EMM = −0.08, 95% CI = −0.49,
0.33; P = 0.034) (Figure 2C).
Cognition: exploratory analysis
Learning and recall.
A significant main effect of treatment for word recognition
was identified [F(2, 1306.00) = 4.42, P = 0.012], with post
hoc comparisons identifying the DHA-rich (EMM = 851.67;
95% CI = 836.39, 866.94; P = 0.009) but not the EPA-rich
(EMM = 869.23; 95% CI = 854.52, 883.94; P = 0.281) group
as having significantly faster RTs during the word learning trials
compared with placebo (EMM = 885.18; 95% CI = 869.64,
900.72) (Figure 3). No other significant effects of treatment or
significant interaction effects between treatment and visit were
identified for any of the other outcomes from the learning or recall
tasks.
Morning cognitive performance.
There were no significant main effects of treatment or
significant interactions between treatment and visit for any of the
cognitive tasks.
Mood




There were no significant main or interaction effects of
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FIGURE 4 Estimated marginal means ± SEs from LMM analysis for
post-dose quantities (μM) of oxy-Hb, in the right PFC, during the serial
subtraction tasks. In the right hemisphere, placebo vs, DHA-rich (P = 0.060);
placebo vs, EPA-rich (P = 0.082). LMM, linear mixed model; Oxy-Hb,
oxygenated hemoglobin; PFC, prefrontal cortex.
NIRS: active period.
A significant interaction between treatment and hemisphere
was identified for oxy-Hb [F(2, 256.55) = 4.95, P = 0.008], with
both the EPA (EMM = 24.97 μM; 95% CI = 23.35, 26.59 μM;
P = 0.082) and DHA (EMM = 24.62 μM; 95% CI = 22.75,
26.48 μM; P = 0.060) groups showing a trend towards
significantly lower oxy-Hb in the right hemisphere compared
with the placebo group (EMM = 27.36 μM; 95% CI = 25.73,
28.98 μM) during completion of the subtraction tasks (Figure 4).
A significant interaction between treatment and hemisphere
was also identified for t-Hb [F(2,251.24) = 3.65, P = 0.027];
however, post hoc comparisons revealed no significant group
differences.
NIRS: serial subtraction and VAS analysis.
There were no significant main or interaction effects of
treatment for the serial subtraction tasks. However, a significant
effect of treatment was identified for ratings of subjective
task difficulty [F(2, 56.99) = 3.91, P = 0.026], with the
DHA-rich (EMM = 50.18; 95% CI = 45.58, 54.86) group rating
the tasks more difficult than the placebo group (EMM = 42.01;
95 CI = 38.06, 45.95; P = 0.028).
NIRS: EI.
No significant main effect of treatment or interactions between
treatment and any other factors were identified.
NIRS: exploratory analysis
Pearson’s bivariate correlations identified significant negative
correlations at both baseline and week 26 assessments, in the right
hemisphere, between oxy-Hb and n–3 index during completion
of the serial 3s (baseline: r = −0.27, P = 0.024; week 26: r =
−0.25, P = 0.048), serial 7s (baseline: r = −0.28, P = 0.017;
week 26: r = −0.25, P = 0.041), and serial 17s (baseline:
r = −0.29, P = 0.013; week 26: r = −0.26, P = 0.038)
tasks (Figure 5). Using Fisher’s Z-transformation to compare
baseline and week 26 correlations (37), no significant differences
were observed for any of the subtraction tasks between time
points (serial 3s: Fisher’s Z = −0.13, P = 0.448; serial 7s:
Fisher’s Z = −0.20, P = 0.422; serial 17s: Fisher’s Z = −0.20,
P = 0.422). No significant correlations were identified in the left
hemisphere.
Discussion
The results of the current research reveal that 26 wk of
supplementation with EPA-rich oil improved global cognitive
function in terms of both speed and accuracy, compared with
placebo and DHA-rich oil. EPA-rich oil also significantly
increased the accuracy of performing all the memory tasks
compared with the DHA-rich oil. Compared with placebo, DHA-
rich oil improved RT during word recognition compared with
placebo during the learning phase of the overnight memory
consolidation tasks. With regard to the cerebral blood flow
parameters, both the EPA- and DHA-rich oils showed trends
towards lower oxy-Hb in the right PFC during completion of
serial subtraction tasks. There were no significant effects of
either treatment on mood, learning-memory recall tasks, waking
cognitive performance, or morning alertness.
To our knowledge, the current trial is the first to investigate
and identify significant improvements in healthy young adults in
both global accuracy and speed of cognitive function following
supplementation with EPA-enriched oil compared with placebo.
These results extend previous findings in healthy older adults,
where observational data have revealed a positive relation
between EPA status and global cognitive function (38, 39),
and beneficial effects of EPA-rich treatments on executive
functions have also been observed (40). Collectively, these
findings are interesting as they suggest that, although EPA is
stored in the brain in low amounts (41), it may still play
an important role in higher-order cognitive functions, as has
been suggested previously (13). In contrast, and somewhat
surprisingly, these beneficial effects were not seen following the
DHA-rich oil, where improvements to cognition were limited
to improved word recognition RTs during the learning phase
of the overnight memory consolidation tasks. In fact, direct
comparisons between the active treatments revealed that global
speed and accuracy and accuracy of memory were improved
following the EPA-rich oil in comparison to the DHA-rich
oil. These results indicate that supplementation with EPA over
DHA may be more beneficial in healthy young adults in terms
of cognitive outcomes. It also demonstrates that the ratio of
EPA and DHA in the investigational treatments provided to
participants could be an important consideration that can greatly
influence study outcomes. Given the emphasis on DHA in
the literature to date, if supplementation with DHA is indeed
less relevant in healthy young populations, this may in part
explain the limited effects that have been reported previously
(4, 6).
Controlled trials published by our laboratory and others
have sought to develop the hypothesis that the effects of n–
3 PUFAs on cognitive function in humans are at least in
part underpinned by their effects on cerebrovascular perfusion
and/or neurovascular coupling. Interestingly, whereas previous
trials have demonstrated an increase in localized cerebral blood
flow (4, 17) or cerebrovascular reactivity (15) following n–
3 PUFAs, the current data reveal a trend towards decreased
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FIGURE 5 Pearson’s bivariate correlations during the serial subtraction tasks between oxy-Hb quantities (μM) in the right PFC and n–3 index at baseline
(n = 78) and week 26 (n = 75). Oxy-Hb, oxygenated hemoglobin; PFC, prefrontal cortex.
of serial subtraction tasks following both active treatments
compared with placebo. As increases in oxy-Hb are usually
interpreted as augmented activation within the brain region
where the measurement is being made (16), the trend towards
decreased quantities of oxy-Hb observed here suggests that there
was less activation in the PFC during completion of the serial
subtraction tasks. However, as this comparative reduction in
activation had no associated cost on performance during the serial
subtraction tasks, these findings could be interpreted within a
neural efficiency framework. The neural efficiency hypothesis
proposes that the inverse relation between total cortical activation
and intelligence results from more focused cortical activation
and strengthened communication between brain regions (42).
Interestingly, the exploratory correlations between the n–3 index
and NIRS parameters revealed inverse associations, even prior to
treatment, again suggestive of enhanced efficiency with increased
n–3 PUFA status. These findings are somewhat at odds with
what has been reported previously, as the only other trials to
our knowledge that have directly compared the effects of EPA-
and DHA-enriched treatments on concurrent brain activity and
cognitive function found evidence of increased neural efficiency
following oils enriched with EPA but not DHA (11, 12). This may
be due to any number of factors, including important differences
in the measurement techniques used (visual evoked potentials,
fMRI) and treatment duration (4 wk, 30 d). However, it is
important to note that the current trial revealed statistical trends
only and the suggested effects should be verified with further
investigation.
Taking the findings from the current NIRS assessments at
face value, we found no evidence of a difference between the
treatments on these outcomes, which fits with previous evidence
that supports a role for both EPA and DHA in modulating
cerebrovascular function (e.g., 15, 17). Comparing this with the
observed differences on the cognitive measures, it follows that
other mechanisms unique to the actions of EPA must underpin
these disparate effects. Possibilities here include the displacement
of membrane-bound arachidonic acid (20:4n−6) by EPA and
subsequent attenuation of the production of proinflammatory
eicosanoids (43), its effects on mitochondrial metabolism
(11), or indeed another mechanism not currently fully
understood.
With regard to memory consolidation, we observed no effects
of EPA- or DHA-rich oil during completion of the recall
tasks, implemented as a proxy measure of overnight memory
consolidation. These findings seem to be at odds with previous in
vitro and in vivo research, which identifies positive effects of n–
3 PUFAs on long-term potentiation (LTP) and synaptic plasticity
(44, 45), as well as on learning memory tasks in humans (20–23).
We aimed to gather learning-memory data as only a small number
of trials have used learning-memory tasks likely to induce LTP
and memory consolidation. While we observed an improvement
in RT following the DHA-rich oil during the learning phase
of the word recognition task, the null recall results do appear
to contradict the limited previous findings (20, 21, 23). These
disparate findings may be due to possible limitations of the novel
overnight recall protocol used here, such as the use of COMPASS
in a nonlaboratory environment where participants might not
have been free from distraction, or the learning tasks themselves,
which have not previously been used to assess learning over an
extended period, for example.
The current trial addresses several limitations that have been
present in previous controlled trials with regard to sample
size, supplementation period, and dosage (4, 5, 7, 8). We
also implemented standardized computerized cognitive testing,
SMEDS-formulated treatments to improve bioavailability, and a
protocol that allowed for a direct comparison of the effects of oils
rich in both EPA and DHA across a range of different outcomes.
With regard to cognition, our results suggest that, at the doses
provided, EPA is more beneficial than DHA in healthy, young
adults. One consideration here is the nature of the participants
included in the trial, who were indeed healthy and, on average, did
not have a very low n–3 status (≤4%) at baseline (46). A recent
systematic review recommends recruiting participants with an n–
3 index of <6% into trials of n–3 PUFAs (47), whereas another
concluded that n–3 PUFA supplementation may only benefit
those who are deficient in them to start with (6). Over one-third of
participants exceeded the recommended index of 6% at baseline,
which may comprise a limitation of the trial. Taking baseline n–3
PUFA status of the trial participants together with the disparate
findings for the 2 enriched oils, one could perhaps conclude
that supplementation with DHA specifically is less relevant in
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or that a higher dose of DHA must be administered in order to
achieve an effect on cognition. This may be the reason why we
found null results in the DHA group, compared with the positive
effects reported by Stonehouse et al. (19), who assessed cognitive
function following 6 mo of daily supplementation with 1.16 g
DHA + 0.17 g EPA using a similar battery of tasks and composite
scores. Finally, as a recent systematic review has identified sex as
an influencing factor on human n–3 PUFA concentrations (48),
it may be useful for future trials to consider including sex as an
independent variable as standard, as has been done previously
(15, 19).
In conclusion, EPA-rich oil improved global cognitive function
in healthy young adults who habitually consume low amounts
of oily fish. The findings also provide further evidence that sup-
plementation with both EPA and DHA may positively influence
neural efficiency, although these results need further exploration.
Overall, the findings highlight unique and overlapping functions
of EPA and DHA, which future trials should seek to compare
further with regard to optimal health benefits.
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